AgingResearch.NewsJoin free

TT-P34

TT-P34 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 9, 2026: “Peptide improved movement in mouse models of brain disease”.

Intervention

1 paper studies it4 findingsUpdated

More peptides

1 new paper in 30 daysSee all 1 papers on TT-P34

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: CHDI Foundation and 5 more
  • 4 of 4 findings with company ties
  • Animals1

What did studies of TT-P34 find?

4

Studies of TT-P34 measured 4 outcomes, among them dopaminergic neuron loss, motor function and synaptic and mitochondrial signatures.

Dopaminergic neuron loss

downin mice1

1 study

  1. TT-P34 protects against dopaminergic neuron loss in mice (MPTP-induced mouse model of Parkinson's disease).

    “treatment of the mitochondria-deficient MPTP-induced mouse model of Parkinson's Disease leads to amelioration of motor deficits and preserves dopaminergic neurons.”

    AnimalsMPTP-induced mouse model of Parkinson's diseasedopaminergic neuron

    Peptide improved movement in mouse models of brain disease

    Acta neuropathologica communications

Motor function

upin mice1

1 study

  1. TT-P34 improves motor function in mice (MPTP-induced mouse model of Parkinson's disease).

    “treatment of the mitochondria-deficient MPTP-induced mouse model of Parkinson's Disease leads to amelioration of motor deficits and preserves dopaminergic neurons.”

    AnimalsMPTP-induced mouse model of Parkinson's disease

    Peptide improved movement in mouse models of brain disease

    Acta neuropathologica communications

Synaptic and mitochondrial signatures

downin mice1

1 study

  1. TT-P34 protects against synaptic and mitochondrial signatures in mice (zQ175 mouse model of Huntington's disease).

    “TT-P34, rescues motor and behavioral deficits and preserves synaptic and mitochondrial signatures in the striatum.”

    AnimalszQ175 mouse model of Huntington's diseaselipidated macrocyclestriatum

    Peptide improved movement in mouse models of brain disease

    Acta neuropathologica communications

More on Synaptic and mitochondrial signatures

Motor and behavioral function

upin mice1

1 study

  1. TT-P34 improves motor and behavioral function in mice (zQ175 mouse model of Huntington's disease).

    “TT-P34, rescues motor and behavioral deficits and preserves synaptic and mitochondrial signatures in the striatum.”

    AnimalszQ175 mouse model of Huntington's diseaselipidated macrocycle

    Peptide improved movement in mouse models of brain disease

    Acta neuropathologica communications

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months
Acta Neuropathologica Communications

Peptide improved movement in mouse models of brain disease

Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.

Mouse studyInterventions
Paper

Related